综述文章:炎症性肠病抗肿瘤坏死因子治疗药物监测的共识声明
由25位澳大利亚及国际专家组成的委员会经系统文献检索后采用改良德尔菲法3轮匿名投票,24条声明中22条达成共识。共识支持治疗药物监测用于优化抗肿瘤坏死因子药物治疗炎症性肠病,尤其在治疗失败时。
要点
- 抗肿瘤坏死因子药物治疗失败、诱导成功后、考虑药物假期及临床缓解期结果会改变管理时可行治疗药物监测。
- 管腔型炎症性肠病达临床缓解的英夫利西单抗谷浓度为3-8 μg/mL,阿达木单抗为5-12 μg/mL。
- 治疗失败时治疗药物监测可识别机制以指导后续决策;稳定临床应答中监测指导给药可能避免未来复发。
核心结论
- 共识声明支持治疗药物监测在优化抗肿瘤坏死因子药物治疗炎症性肠病中的作用,尤其是在治疗失败的情况下。
研究设计与样本
- 由25位澳大利亚及国际专家组成委员会,经系统文献检索起草初始声明,采用改良德尔菲技术进行3轮匿名投票与反馈修改,80%同意且无或仅有轻微保留的声明被接受。
主要发现
- 24条声明中22条达到共识标准。
- 治疗失败时、诱导成功后、考虑药物假期时以及临床缓解期仅当结果会改变管理时,应进行抗肿瘤坏死因子药物治疗药物监测。
- 管腔型炎症性肠病达临床缓解时,英夫利西单抗谷浓度3-8 μg/mL与阿达木单抗谷浓度5-12 μg/mL被认为合适,不同疾病表型或治疗终点(如瘘管性疾病或黏膜愈合)范围可能不同。
- 治疗失败时治疗药物监测可识别机制以指导后续决策;稳定临床应答中监测指导给药可能避免未来复发。
- 数据表明药物耐受性抗药抗体检测相对于药物敏感性检测不具优势;推荐非抗肿瘤坏死因子生物制剂进行监测前需更多数据。
关键数值与推荐
- 24条声明中22条符合共识标准。
- 英夫利西单抗谷浓度3-8 μg/mL、阿达木单抗谷浓度5-12 μg/mL用于管腔型炎症性肠病达临床缓解。
临床怎么用
- 原文未据此给出推荐。
局限性
- 推荐非抗肿瘤坏死因子生物制剂进行药物监测前需更多数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) patients receiving anti-tumour necrosis factor (TNF) agents can help optimise outcomes. Consensus statements based on current evidence will help the development of treatment guidelines. AIM: To develop evidence-based consensus statements for TDM-guided anti-TNF therapy in IBD. METHODS: A committee of 25 Australian and international experts was assembled. The initial draft statements were produced following a systematic literature search. A modified Delphi technique was used with 3 iterations. Statements were modified according to anonymous voting and feedback at each iteration. Statements with 80% agreement without or with minor reservation were accepted. RESULTS: 22/24 statements met criteria for consensus. For anti-TNF agents, TDM should be performed upon treatment failure, following successful induction, when contemplating a drug holiday and periodically in clinical remission only when results would change management. To achieve clinical remission in luminal IBD, infliximab and adalimumab trough concentrations in the range of 3-8 and 5-12 μg/mL, respectively, were deemed appropriate. The range may differ for different disease phenotypes or treatment endpoints-such as fistulising disease or to achieve mucosal healing. In treatment failure, TDM may identify mechanisms to guide subsequent decision-making. In stable clinical response, TDM-guided dosing may avoid future relapse. Data indicate drug-tolerant anti-drug antibody assays do not offer an advantage over drug-sensitive assays. Further data are required prior to recommending TDM for non-anti-TNF biological agents. CONCLUSION: Consensus statements support the role of TDM in optimising anti-TNF agents to treat IBD, especially in situations of treatment failure.
引用
- Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017. PMID: 29027257. doi:10.1111/apt.14368
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。